Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
125 Leser
Artikel bewerten:
(0)

Elsevier Features Award-winning Integrated Clinical Decision Support Solutions at HIMSS17

PHILADELPHIA, February 17, 2017 /PRNewswire/ --

Care Planning, a 2017 KLAS Category Leader Award winner, to be featured with Elsevier's other world-class clinical decision support solutions

Elsevier, a world-leading provider of scientific, technical and medical information products and services, will showcase its Integrated Clinical Decision Support solutions at booth #2961 at the Healthcare Information and Management Systems Society (HIMSS) 2017 annual meeting in Orlando, Fla, Feb. 19-23.

A leader in bringing evidence-based content into the care process, Elsevier focuses on encouraging quality, enhancing efficiency and improving outcomes - providing empowering knowledge that enables action at the point of care. Representatives from Elsevier's Clinical Solutions will be available to discuss how active clinical decision support solutions and integrated clinical content and information at the point of care can improve care delivery.

"With the changing healthcare landscape, Elsevier is uniquely positioned to partner with healthcare providers to improve clinical outcomes," said Dr. John Danaher, President, Clinical Solutions at Elsevier. "Our solutions span the entire care continuum, across care settings and consider the patient at the center of care delivery. The recent recognition of Elsevier's Care Planning with the 2017 Best in KLAS award affirms our leadership in innovative, easy-to-use, high-quality evidence-based solutions integrated into healthcare systems and clinical workflows."

"We are proud of our collaborations with our customers to advance the practice of interprofessional care teams and engagement of patients in support of exceptional patient care," Danaher said.

Elsevier will also be highlighting new clinical pathway technology during the HIMSS interoperability showcase. This innovation will be demonstrated via a community care use case scenario.

Elsevier is also celebrating the distinction of HIMSS 2016 Book of the Year Award toHealth Information Exchange: Navigating and Managing a Network of Health Information Systems. Edited by Brian E. Dixon, PhD, FHIMSS, an Associate Professor at the IU Richard M. Fairbanks School of Public Health and Research Scientist at the Regenstrief Institute, the book was published in March 2016 by Elsevier's Academic Press.

For more information on Elsevier HIMSS activities, visit Elsevier's Clinical Solutions HIMSS17 website.

---

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Research Intelligenceand ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.www.elsevier.com

Media contact
Christopher Capot
Director, Corporate Relations, Elsevier
+1-917-704-5174
c.capot@elsevier.com


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.